Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity

B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was pre...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 55; no. 2; pp. 263 - 267
Main Authors Matsushita, Takashi, Hamaguchi, Yasuhito, Hasegawa, Minoru, Takehara, Kazuhiko, Fujimoto, Manabu
Format Journal Article
LanguageEnglish
Published England 01.02.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients. Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment. The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc. These results suggest that decreased Breg cell levels may contribute to the development of SSc.
AbstractList B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients. Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment. The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc. These results suggest that decreased Breg cell levels may contribute to the development of SSc.
B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.OBJECTIVEB cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.METHODSBlood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.RESULTSThe frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.These results suggest that decreased Breg cell levels may contribute to the development of SSc.CONCLUSIONThese results suggest that decreased Breg cell levels may contribute to the development of SSc.
Author Takehara, Kazuhiko
Matsushita, Takashi
Hasegawa, Minoru
Fujimoto, Manabu
Hamaguchi, Yasuhito
Author_xml – sequence: 1
  givenname: Takashi
  surname: Matsushita
  fullname: Matsushita, Takashi
– sequence: 2
  givenname: Yasuhito
  surname: Hamaguchi
  fullname: Hamaguchi, Yasuhito
– sequence: 3
  givenname: Minoru
  surname: Hasegawa
  fullname: Hasegawa, Minoru
– sequence: 4
  givenname: Kazuhiko
  surname: Takehara
  fullname: Takehara, Kazuhiko
– sequence: 5
  givenname: Manabu
  surname: Fujimoto
  fullname: Fujimoto, Manabu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26350483$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1OxCAUhYnR-P8EJoalm1EoHYa6818TEze6bijcjmhbRi4d00fwrWVm1BgXriCX79x7OWeHrHe-A0IOODvmrBAn4Rn6Vkff-Olw8gpzIfga2ea5zEZMiGz9557lW2QH8YUxNuZCbZKtTIoxy5XYJh-XYAJoBEsbmEOD1Nc0wLRvUucw0HNqoElV19GZjg66iPTdxWeKA0ZonaFoGggeHZ5SjeiNS5jvVpDuo9dddJW3A50Fb3uzfNSdpdbhYi7VqTR3cdgjG7VuEPa_zl3ydH31eHE7un-4ubs4ux-ZtHMcKcWE5JIXUHM-VnbCjeXKWFEAr2FSVJWEupK5rmUlikxYXWVc54XIVKWsycQuOVr1Tfu89YCxbB0uPqk78D2WfCKZknxcLNDDL7SvWrDlLLhWh6H8ti8BYgWY5AAGqH8QzspFSOXvkMpVSElV_FEZF5euxaBd86_2E_ZNomE
CitedBy_id crossref_primary_10_3390_biomedicines10092150
crossref_primary_10_1186_s13075_016_1213_9
crossref_primary_10_1093_postmj_qgae169
crossref_primary_10_1038_s41584_019_0184_z
crossref_primary_10_1111_cei_13238
crossref_primary_10_1016_j_jid_2021_05_038
crossref_primary_10_3390_ph15080936
crossref_primary_10_2336_nishinihonhifu_83_397
crossref_primary_10_1111_imr_12941
crossref_primary_10_1371_journal_pone_0180726
crossref_primary_10_1016_j_rcreu_2023_09_001
crossref_primary_10_1111_jth_14427
crossref_primary_10_1016_j_autrev_2025_103782
crossref_primary_10_1136_ard_2021_221925
crossref_primary_10_1111_1346_8138_13994
crossref_primary_10_1016_j_autrev_2017_10_015
crossref_primary_10_1016_j_semarthrit_2018_10_007
crossref_primary_10_1016_j_jaut_2020_102526
crossref_primary_10_1038_srep27479
crossref_primary_10_1016_j_clim_2024_110195
crossref_primary_10_1093_rheumatology_keab257
crossref_primary_10_3389_fimmu_2022_1075813
crossref_primary_10_1111_cei_13501
crossref_primary_10_1016_j_jdermsci_2018_11_008
crossref_primary_10_1186_s13075_020_02153_8
crossref_primary_10_3390_ijms25010583
crossref_primary_10_3389_fphar_2022_826839
crossref_primary_10_1007_s00109_024_02424_w
crossref_primary_10_3389_fimmu_2022_933468
crossref_primary_10_1016_j_clim_2017_04_013
crossref_primary_10_3389_fimmu_2017_00053
crossref_primary_10_3389_fimmu_2024_1328785
crossref_primary_10_1007_s00296_020_04658_6
crossref_primary_10_1007_s10067_021_05665_z
crossref_primary_10_1016_j_revmed_2016_02_016
crossref_primary_10_1016_j_imlet_2019_08_004
crossref_primary_10_3389_fmed_2022_936182
crossref_primary_10_1186_s42358_024_00401_y
crossref_primary_10_1186_s13075_020_02226_8
crossref_primary_10_1002_kjm2_12505
crossref_primary_10_1007_s00296_018_4076_3
crossref_primary_10_3389_fimmu_2022_999008
crossref_primary_10_3390_ph16081066
crossref_primary_10_1093_rheumatology_keac578
crossref_primary_10_1007_s10067_024_07086_0
crossref_primary_10_1016_j_jneuroim_2021_577520
crossref_primary_10_1016_j_imlet_2018_01_002
crossref_primary_10_1172_JCI85113
crossref_primary_10_1371_journal_pbio_3001513
crossref_primary_10_3389_fimmu_2018_00835
crossref_primary_10_3390_biology12020285
crossref_primary_10_3389_fimmu_2024_1373464
crossref_primary_10_1080_00207454_2023_2254922
crossref_primary_10_1111_1756_185X_13764
crossref_primary_10_1038_s41598_021_81588_8
crossref_primary_10_1111_bjd_15113
crossref_primary_10_3390_cells9010077
crossref_primary_10_1182_bloodadvances_2017011072
crossref_primary_10_1002_cia2_12059
crossref_primary_10_1016_j_autrev_2020_102730
crossref_primary_10_1007_s12026_018_8998_3
crossref_primary_10_1016_j_jcyt_2021_12_002
crossref_primary_10_1111_1346_8138_15117
crossref_primary_10_1093_rheumatology_keaa186
crossref_primary_10_1186_s42358_022_00279_8
crossref_primary_10_1016_j_rcreue_2024_05_002
crossref_primary_10_3389_fimmu_2022_941011
crossref_primary_10_1093_intimm_dxac048
crossref_primary_10_1126_sciadv_aas9944
crossref_primary_10_3389_fimmu_2022_921260
crossref_primary_10_3389_fimmu_2018_00622
crossref_primary_10_1093_stcltm_szad010
crossref_primary_10_3389_fimmu_2022_925741
crossref_primary_10_3389_fimmu_2021_773896
crossref_primary_10_1002_cia2_12288
crossref_primary_10_1016_j_jdermsci_2020_12_007
crossref_primary_10_3389_fimmu_2018_02241
crossref_primary_10_1016_j_jmb_2020_10_019
crossref_primary_10_4049_jimmunol_1801211
crossref_primary_10_1093_cei_uxac104
Cites_doi 10.1016/j.immuni.2009.11.009
10.1182/blood-2010-07-294249
10.1002/art.1780230510
10.1002/art.20274
10.1182/blood-2012-11-465658
10.1007/BF00870304
10.2353/ajpath.2006.060205
10.1093/rheumatology/40.10.1135
10.1002/art.27233
10.1093/rheumatology/keu463
10.1002/art.22811
10.1038/sj.jid.5700919
10.1172/JCI36030
10.1002/art.34359
10.1002/art.1780251101
10.1056/NEJM197502132920706
10.1002/art.1780370313
10.1016/j.jdermsci.2010.08.010
ContentType Journal Article
Copyright The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/rheumatology/kev331
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 267
ExternalDocumentID 26350483
10_1093_rheumatology_kev331
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGORE
AGQPQ
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
CITATION
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c350t-880361619ef1158d71cd18cd39e1fe79bb6efb64af6b3923dab21a49328b8dc23
ISSN 1462-0324
1462-0332
IngestDate Fri Jul 11 11:14:50 EDT 2025
Mon Jul 21 05:51:09 EDT 2025
Thu Apr 24 22:53:00 EDT 2025
Tue Jul 01 01:36:34 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords IL-10
regulatory B cell
systemic sclerosis
Language English
License The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c350t-880361619ef1158d71cd18cd39e1fe79bb6efb64af6b3923dab21a49328b8dc23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/rheumatology/article-pdf/55/2/263/17389189/kev331.pdf
PMID 26350483
PQID 1760861592
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_1760861592
pubmed_primary_26350483
crossref_primary_10_1093_rheumatology_kev331
crossref_citationtrail_10_1093_rheumatology_kev331
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-02-00
2016-Feb
20160201
PublicationDateYYYYMMDD 2016-02-01
PublicationDate_xml – month: 02
  year: 2016
  text: 2016-02-00
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2016
References 2016011223140161000_55.2.263.15
2016011223140161000_55.2.263.14
2016011223140161000_55.2.263.17
2016011223140161000_55.2.263.16
2016011223140161000_55.2.263.19
2016011223140161000_55.2.263.18
2016011223140161000_55.2.263.2
2016011223140161000_55.2.263.3
2016011223140161000_55.2.263.4
2016011223140161000_55.2.263.11
2016011223140161000_55.2.263.10
LeRoy (2016011223140161000_55.2.263.1) 1988; 15
2016011223140161000_55.2.263.13
2016011223140161000_55.2.263.12
2016011223140161000_55.2.263.9
2016011223140161000_55.2.263.5
2016011223140161000_55.2.263.6
2016011223140161000_55.2.263.7
2016011223140161000_55.2.263.8
References_xml – ident: 2016011223140161000_55.2.263.8
  doi: 10.1016/j.immuni.2009.11.009
– ident: 2016011223140161000_55.2.263.7
  doi: 10.1182/blood-2010-07-294249
– ident: 2016011223140161000_55.2.263.10
  doi: 10.1002/art.1780230510
– ident: 2016011223140161000_55.2.263.2
  doi: 10.1002/art.20274
– ident: 2016011223140161000_55.2.263.6
  doi: 10.1182/blood-2012-11-465658
– ident: 2016011223140161000_55.2.263.15
  doi: 10.1007/BF00870304
– ident: 2016011223140161000_55.2.263.4
  doi: 10.2353/ajpath.2006.060205
– ident: 2016011223140161000_55.2.263.14
  doi: 10.1093/rheumatology/40.10.1135
– ident: 2016011223140161000_55.2.263.18
  doi: 10.1002/art.27233
– ident: 2016011223140161000_55.2.263.5
  doi: 10.1093/rheumatology/keu463
– ident: 2016011223140161000_55.2.263.9
  doi: 10.1002/art.22811
– ident: 2016011223140161000_55.2.263.3
  doi: 10.1038/sj.jid.5700919
– ident: 2016011223140161000_55.2.263.17
  doi: 10.1172/JCI36030
– ident: 2016011223140161000_55.2.263.19
  doi: 10.1002/art.34359
– ident: 2016011223140161000_55.2.263.11
  doi: 10.1002/art.1780251101
– ident: 2016011223140161000_55.2.263.12
  doi: 10.1056/NEJM197502132920706
– ident: 2016011223140161000_55.2.263.13
  doi: 10.1002/art.1780370313
– volume: 15
  start-page: 202
  year: 1988
  ident: 2016011223140161000_55.2.263.1
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
  publication-title: J Rheumatol
– ident: 2016011223140161000_55.2.263.16
  doi: 10.1016/j.jdermsci.2010.08.010
SSID ssj0005138
Score 2.4618392
Snippet B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 263
SubjectTerms Adolescent
Adult
Aged
Autoantibodies - biosynthesis
Autoantibodies - immunology
Autoimmunity
B-Lymphocytes, Regulatory - immunology
B-Lymphocytes, Regulatory - metabolism
B-Lymphocytes, Regulatory - pathology
Disease Progression
Female
Flow Cytometry
Follow-Up Studies
Humans
Interleukin-10 - metabolism
Lymphocyte Count
Male
Middle Aged
Scleroderma, Systemic - immunology
Scleroderma, Systemic - metabolism
Scleroderma, Systemic - pathology
Severity of Illness Index
Young Adult
Title Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity
URI https://www.ncbi.nlm.nih.gov/pubmed/26350483
https://www.proquest.com/docview/1760861592
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWGIiE2iDfDS0ZiV0LHcSaTsKM8VCENCzSVZhfZsd1GU5Jqkqilf8D38INcvxJXUARsooyTOEruGd97neNzEXpJuBKZXFAA75xGCYMYLqckjtScCPBAc8KYnodcfk4PDpNP6_l6MvkRsJb6jr8uL367ruR_rAptYFe9SvYfLDt0Cg2wD_aFLVgYtn9l4_cm5mshZjzR3B_Dytja4vL60_n-rp6Wt0RxK5_q1rJZ-eaq3G2hQ3CTleHFsdFSbslb3zXw4iveiG-ayCV6V1e8Fv7DjtHi0OUnwiD3y7HsIRC26k5azvTcM-hdyZBg-mHJurZvjysbxK7YRhd3CqbV2ZGu1mIcBWt7OK8ZD7byiJ0xS_6vm20_zkJspNahtmyRC7hq04SzG2QgRGvnZEfkJIUWSi8N2VbZ10EzDsdfO1r-4hesZtY2eHz4CVZ1y8UCrJx-NWDRGj1abX90kwN50R-6hq7HkJuYFebrgFdEaOblrXK6F95zz95RC1C7Pi5HQ1ekOCbUWd1Gt1yOgt9awN1BE1nfRTeWjoVxD30fcIct7nCj8Ig7vI8N7nBVY487rAGFPe7wgLs3OECdPSlEHR5RhwE32KEOe9TdR4cfP6zeHUSupEdUwgN3EXgLmkKSkUsFqUgmFqQUJCsFzSVRcpFznkrF04SplEPkTgXjMWEJJBkZz0QZ0wdop25q-QhhpSB1nnFI9xOVaA0iVSZlRmZMEUYXMpui2L_aonR697rsyklheRe0CE1TWNNM0avholMr9_Ln0194mxUwLOuXy2rZ9G1BFuksg2whj6fooTXm0KE3_uMrjzxBN8c_w1O00217-QyC344_N2D7CeeQvgc
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+levels+of+regulatory+B+cells+in+patients+with+systemic+sclerosis%3A+association+with+autoantibody+production+and+disease+activity&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Matsushita%2C+Takashi&rft.au=Hamaguchi%2C+Yasuhito&rft.au=Hasegawa%2C+Minoru&rft.au=Takehara%2C+Kazuhiko&rft.date=2016-02-01&rft.eissn=1462-0332&rft.volume=55&rft.issue=2&rft.spage=263&rft_id=info:doi/10.1093%2Frheumatology%2Fkev331&rft_id=info%3Apmid%2F26350483&rft.externalDocID=26350483
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon